Vera Therapeutics, Inc. – NASDAQ:VERA

Add to watchlist

$21.81

-19.59

-47.33%

Market closed

Open in 1 day

+13.08%

month

+13.08%

quarter

+159.95%

year

Market Cap	2.67B
Enterprise value	150.97M

P/E	-1.97
EV/Sales	N/A
EV/EBITDA	-1.25
Price/Sales	N/A
Price/Book	2.12
PEG ratio	-0.03
EPS	-2.05

Revenue	N/A
EBITDA	-100.70M
Income	-94.30M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Vera Therapeutics, Inc. (NASDAQ:VERA): Profit margin
Jun 2023	0	-20.16M
Sep 2023	0	-20.10M
Dec 2023	0	-25.65M
Mar 2024	0	-28.38M

Vera Therapeutics Financials Estimate

Q Y

Vera Therapeutics, Inc. (NASDAQ:VERA): Analyst Estimates
Sep 2025	0	-27.78M
Oct 2025	0	-31.77M
Dec 2025	0	-19.51M
Dec 2025	0	-34.58M

Analysts Price target
Financials & Ratios estimates

Vera Therapeutics, Inc. (NASDAQ:VERA): Earnings per share (EPS)
2024-03-20	-0.53	-0.58
2024-05-09	-0.53	-0.56

Vera Therapeutics, Inc. (NASDAQ:VERA): Debt to assets
Jun 2023	195178000	54.65M	28%
Sep 2023	175618000	51.91M	29.56%
Dec 2023	175546000	73.86M	42.08%
Mar 2024	419356000	65.81M	15.69%

Vera Therapeutics, Inc. (NASDAQ:VERA): Cash Flow
Jun 2023	-17.77M	-86.44M	432K
Sep 2023	-22.97M	16.22M	297K
Dec 2023	-25.14M	18.55M	24.82M
Mar 2024	-33.83M	-219.28M	276.54M

Vera Therapeutics alternative data

Vera Therapeutics, Inc. (NASDAQ:VERA): Employee count
Aug 2023	46
Sep 2023	49
Oct 2023	49
Nov 2023	49
Dec 2023	49
Jan 2024	49
Feb 2024	49
Mar 2024	51
Apr 2024	51
May 2024	51
Jun 2024	55
Jul 2024	55

Vera Therapeutics
Hedge Funds Holdings Q1 2023

57.43% -20.95%

of VERA is owned by hedge funds

31 -27

hedge funds hold VERA stock

15.25M -6.07M

shares is hold by hedge funds

VERA hedge funds holdings changes

Vera Therapeutics
Insider Trading

Vera Therapeutics, Inc. (NASDAQ:VERA): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	161290	1050000
Mar 2024	0	834459
Apr 2024	0	124191
May 2024	0	30837
Aug 2024	0	60416
Sep 2024	0	54326
Oct 2024	0	50000
Nov 2024	0	50000
Dec 2024	0	35000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	19 Dec 2024	FORDYCE MARSHALL director, officer..	Stock Option (Right to Buy)	57,661	$2.9	$167,044
Option	19 Dec 2024	FORDYCE MARSHALL director, officer..	Class A Common Stock	57,661	$2.9	$167,044
Option	18 Dec 2024	FORDYCE MARSHALL director, officer..	Stock Option (Right to Buy)	15,625	$2.9	$45,266
Option	18 Dec 2024	FORDYCE MARSHALL director, officer..	Stock Option (Right to Buy)	1,875	$2.9	$5,432
Option	18 Dec 2024	FORDYCE MARSHALL director, officer..	Class A Common Stock	5,023	$2.9	$14,552
Option	18 Dec 2024	FORDYCE MARSHALL director, officer..	Class A Common Stock	4,635	$2.9	$13,428
Option	18 Dec 2024	FORDYCE MARSHALL director, officer..	Class A Common Stock	3,772	$2.9	$10,927
Option	18 Dec 2024	FORDYCE MARSHALL director, officer..	Class A Common Stock	2,195	$2.9	$6,359
Option	18 Dec 2024	FORDYCE MARSHALL director, officer..	Class A Common Stock	1,875	$2.9	$5,432
Sale	18 Dec 2024	FORDYCE MARSHALL director, officer..	Class A Common Stock	17,500	$43.01	$752,623

VERA insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY Filling date: 16 Feb 2021 Issue date: 8 Jul 2021	16 Feb 2021	8 Jul 2021
Application	Application PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO Filling date: 22 Feb 2021 Issue date: 10 Jun 2021	22 Feb 2021	10 Jun 2021

Vera Therapeutics
Executives

Insider	Age	Since	Compensation
Dr. Marshall Fordyce M.D. (1974) Founder, Pres, Chief Executive Officer & Director	51		$468,000
Dr. Joanne Curley Ph.D. (1969) Chief Devel. Officer	56		$448,750

Vera Therapeutics
Latest News

Monday, 9 December 2024
18:29	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Friday, 22 November 2024
16:05	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Monday, 11 November 2024
16:05	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
11:00	Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet	zacks.com
Friday, 8 November 2024
16:05	Vera Therapeutics to Participate at Upcoming Investor Conferences	globenewswire.com
08:00	Vera Therapeutics to Participate at Upcoming Investor Conferences	globenewswire.com
Tuesday, 29 October 2024
20:21	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock	globenewswire.com
Monday, 28 October 2024
17:37	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock	globenewswire.com
10:33	Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years	benzinga.com
Saturday, 26 October 2024
19:30	Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024	globenewswire.com
Friday, 4 October 2024
16:05	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
13:45	Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients	seekingalpha.com
Wednesday, 2 October 2024
06:30	Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases	globenewswire.com
06:30	Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024	globenewswire.com
Tuesday, 10 September 2024
16:05	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Tuesday, 3 September 2024
07:49	Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says	barrons.com
Friday, 9 August 2024
16:05	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Thursday, 8 August 2024
08:00	Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results	globenewswire.com
Friday, 5 July 2024
16:30	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Tuesday, 11 June 2024
16:01	Vera Therapeutics Appoints Christy J. Oliger to Board of Directors	globenewswire.com
Friday, 7 June 2024
16:05	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
16:05	Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	globenewswire.com
Tuesday, 28 May 2024
08:00	Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)	globenewswire.com
Saturday, 25 May 2024
09:40	Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress	globenewswire.com
Thursday, 9 May 2024
08:00	Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	globenewswire.com
Tuesday, 7 May 2024
16:38	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Saturday, 13 April 2024
05:29	Could This Stock Be the Next Biotech Buyout?	The Motley Fool
Thursday, 11 April 2024
13:41	2 Biotech Stocks Driving the Nasdaq Today	Schaeffers Research
Friday, 12 January 2024
18:44	Why Vera Therapeutics Stock Soared by 22% This Week	The Motley Fool
Friday, 15 December 2023
10:15	This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street	The Motley Fool

Ideas & Opinions

Seeking Alpha 17 Aug 2023

Vera Therapeutics' Promising Atacicept Drug Targets IgAN
Seeking Alpha 4 Jul 2023

Vera: New Kidney Data, May Be A Potential Next Big Pharma M&A Target
Seeking Alpha 3 Jul 2023

Vera: Repurposed Molecule Program Does Not Impress
Seeking Alpha 26 Apr 2023

Strong Small-Cap Insider Buys: Q1 2023
Seeking Alpha 13 Feb 2023

Chinook's Atrasentan: A Promising Solution For IgA Nephropathy?
Seeking Alpha 12 Jan 2023

Vera: Disappointing Data From Phase 2 ORIGIN Trial, Initiating Coverage With A Sell Rating
Seeking Alpha 6 Jan 2023

Chinook Therapeutics: Best Biotech For Kidney Disease Exposure, With Catalysts
Seeking Alpha 31 Aug 2022

Chinook Therapeutics: Multiple Shots On Goal For IgAN
Seeking Alpha 7 Jul 2022

Checking Out Chinook Therapeutics
Seeking Alpha 19 Jan 2022

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Frequently Asked Questions (FAQ)

What's the price of Vera Therapeutics stock today?

One share of Vera Therapeutics stock can currently be purchased for approximately $21.81.
When is Vera Therapeutics's next earnings date?

Unfortunately, Vera Therapeutics's (VERA) next earnings date is currently unknown.
Does Vera Therapeutics pay dividends?

No, Vera Therapeutics does not pay dividends.
How much money does Vera Therapeutics make?

Vera Therapeutics has a market capitalization of 2.67B. Vera Therapeutics made a loss 95.99M US dollars in net income (profit) last year or -$0.56 on an earnings per share basis.
What is Vera Therapeutics's stock symbol?

Vera Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "VERA".
What is Vera Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Vera Therapeutics?

Shares of Vera Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Vera Therapeutics's key executives?
Vera Therapeutics's management team includes the following people:
- Dr. Marshall Fordyce M.D. Founder, Pres, Chief Executive Officer & Director(age: 51, pay: $468,000)
- Dr. Joanne Curley Ph.D. Chief Devel. Officer(age: 56, pay: $448,750)
Is Vera Therapeutics founder-led company?

Yes, Vera Therapeutics is a company led by its founder Dr. Marshall Fordyce M.D..
How many employees does Vera Therapeutics have?

As Jul 2024, Vera Therapeutics employs 55 workers, which is 8% more then previous quarter.
When Vera Therapeutics went public?

Vera Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 14 May 2021.
What is Vera Therapeutics's official website?

The official website for Vera Therapeutics is veratx.com.
Where are Vera Therapeutics's headquarters?

Vera Therapeutics is headquartered at 8000 Marina Boulevard, Brisbane, CA.
How can i contact Vera Therapeutics?

Vera Therapeutics's mailing address is 8000 Marina Boulevard, Brisbane, CA and company can be reached via phone at +65 07700077.

Vera Therapeutics, Inc.

veratx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

+65 07700077

8000 Marina Boulevard
Brisbane, CA 94005

CIK: 0001831828
ISIN: US92337R1014
CUSIP: 92337R101